# Nurix Therapeutics (NRIX) shares surged on Monday after the company entered a global collaboration and licensing agreement with Roche (RHHBY) to develop and commercialize bexobrutideg.

*biotech · news · 2026-06-08 · Seeking Alpha*

## Key points

- Nurix Therapeutics signed a global collaboration and licensing agreement with Roche on bexobrutideg.
- The deal is valued at up to $3 billion, with Nurix receiving $700 million upfront.
- Bexobrutideg is a potential best-in-class oral BTK degrader for cancer therapy.
- Nurix shares surged 43% following the announcement of the Roche collaboration deal.

Nurix surges 43% on up to $3B cancer drug deal with Roche Comments Nurix Therapeutics (NRIX) shares surged on Monday after the company entered a global collaboration and licensing agreement with Roche (RHHBY) to develop and commercialize bexobrutideg, a potential best-in-class oral BTK degrader, in a deal worth up to $3B, including a $700M upfront Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** Roche, Nurix Therapeutics
**Countries:** United States, Switzerland

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4601297-nurix-surges-43-on-up-to-3b-cancer-drug-deal-with-roche)

---

Canonical: https://newsio.io/n/2a2f06a0-114f-4a6b-a10a-ffe09396e50a/nurix-therapeutics-nrix-shares-surged-on-monday-after-the-company-entered-a-glob
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works